JPMorgan Chase & Co. restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Wednesday, AnalystRatings.com reports. They currently have a $85.00 price target on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the company. Cowen restated a buy rating on shares of Gilead Sciences in a research report on Friday, May 3rd. Wells Fargo & Co upgraded Gilead Sciences from a market perform rating to an outperform rating and upped their price objective for the company from $68.00 to $88.00 in a report on Monday, July 15th. Oppenheimer set a $85.00 price objective on Gilead Sciences and gave the company a buy rating in a report on Friday, July 12th. Sanford C. Bernstein began coverage on Gilead Sciences in a report on Friday, April 26th. They issued an outperform rating and a $82.00 price objective for the company. Finally, UBS Group upgraded Gilead Sciences from a neutral rating to a buy rating and upped their price objective for the company from $75.00 to $77.00 in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $82.29.
Shares of GILD stock traded down $0.52 on Wednesday, reaching $64.95. 6,753,067 shares of the stock were exchanged, compared to its average volume of 5,609,861. The company has a market capitalization of $82.80 billion, a PE ratio of 10.56, a PEG ratio of 3.96 and a beta of 1.16. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61. The company has a current ratio of 3.85, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The firm’s 50 day moving average price is $67.21.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.91 earnings per share. As a group, analysts anticipate that Gilead Sciences will post 6.66 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.88%. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now directly owns 27,198 shares in the company, valued at $1,869,862.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares of the company’s stock, valued at $2,238,277.86. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Cpwm LLC boosted its position in shares of Gilead Sciences by 122.5% during the second quarter. Cpwm LLC now owns 29,456 shares of the biopharmaceutical company’s stock worth $1,990,000 after buying an additional 16,219 shares during the period. Cornerstone Wealth Management LLC boosted its position in shares of Gilead Sciences by 10.3% during the second quarter. Cornerstone Wealth Management LLC now owns 4,788 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 448 shares during the period. Financial Sense Advisors Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth about $203,000. McKinley Carter Wealth Services Inc. boosted its position in shares of Gilead Sciences by 6.0% during the second quarter. McKinley Carter Wealth Services Inc. now owns 3,699 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 209 shares during the period. Finally, Everence Capital Management Inc. boosted its position in shares of Gilead Sciences by 13.7% during the second quarter. Everence Capital Management Inc. now owns 26,970 shares of the biopharmaceutical company’s stock worth $1,822,000 after buying an additional 3,240 shares during the period. Institutional investors own 78.85% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.